



10 November 2021

ASX ANNOUNCEMENT

2021 Annual General Meeting – Results of Meeting

Set out below are the results of the 2021 Annual General Meeting (**AGM**) held earlier today. All resolutions put to the AGM were decided by a poll.

Item	Resolution	Result
2	Remuneration Report	Passed as an advisory resolution
3.1	Re-election of Mr Amit Patel	Passed as an ordinary resolution
3.2	Re-election of Mr Donald Williams	Passed as an ordinary resolution
4	Grant of Performance Rights to Mr Richard Carreon	Passed as an ordinary resolution
5	Grant of Options to Mr Richard Carreon	Passed as an ordinary resolution
6	Approval of 10% placement capacity under Listing Rule 7.1A	Passed as a special resolution
7	Approval to issue securities under the Company's Employee Incentive Plan	Passed as an ordinary resolution
8	Amendments to Constitution	Passed as a special resolution
9	Renewal of proportional takeover provision	Passed as a special resolution

In accordance with section 251AA(2) of the *Corporations Act 2001* (Cth) and ASX Listing Rule 3.13.2 the results of the AGM are provided in the attached document.

Authorised for release by the Company Secretary of ImpediMed Limited.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO Digital Health Platform

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire Healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

ANNUAL GENERAL MEETING
Wednesday, 10 November, 2021

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			Result
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	
2	REMUNERATION REPORT	N	583,853,574 98.64%	4,821,516 0.81%	3,248,202 0.55%	1,139,615	592,602,986 99.19%	4,837,078 0.81%	1,139,615	Carried
3.1	RE-ELECTION OF MR AMIT PATEL	NA	596,653,077 98.84%	3,608,880 0.60%	3,418,334 0.57%	22,160	605,588,183 99.41%	3,608,880 0.59%	22,160	Carried
3.2	RE-ELECTION OF MR DONALD WILLIAMS	NA	592,891,495 98.21%	7,366,062 1.22%	3,426,334 0.57%	18,560	601,834,601 98.79%	7,366,062 1.21%	18,560	Carried
4	GRANT OF PERFORMANCE RIGHTS TO MR RICHARD CARREON, CHIEF EXECUTIVE OFFICER AND MANAGING DIRECTOR	NA	588,103,999 97.43%	11,921,921 1.98%	3,571,202 0.59%	105,329	597,176,411 98.04%	11,937,483 1.96%	105,329	Carried
5	GRANT OF OPTIONS TO MR RICHARD CARREON, CHIEF EXECUTIVE OFFICER AND MANAGING DIRECTOR	NA	584,473,590 96.85%	15,659,718 2.59%	3,371,202 0.56%	197,941	591,298,332 97.09%	17,722,950 2.91%	197,941	Carried
6	APPROVAL OF ADDITIONAL 10% CAPACITY TO ISSUE EQUITY SECURITIES UNDER ASX LISTING RULE 7.1A	NA	494,674,001 83.93%	91,429,206 15.51%	3,296,206 0.56%	14,303,038	503,474,479 84.63%	91,441,706 15.37%	14,303,038	Carried
7	APPROVAL TO ISSUE SECURITIES UNDER THE IMPEDIMED EMPLOYEE INCENTIVE PLAN	NA	587,494,522 98.65%	4,679,319 0.79%	3,348,202 0.56%	58,798	596,343,934 99.22%	4,694,881 0.78%	58,798	Carried
8	AMENDMENTS TO CONSTITUTION	NA	543,540,276 90.11%	53,877,620 8.93%	5,768,354 0.96%	516,201	554,812,902 91.15%	53,890,120 8.85%	516,201	Carried
9	RENEWAL OF PROPORTIONAL TAKEOVER PROVISION	NA	594,860,711 98.61%	4,472,421 0.74%	3,924,749 0.65%	444,570	604,302,232 99.27%	4,472,421 0.73%	444,570	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item